Vanderbilt-Ingram website >
Researchers at VUMC are reporting another advance in the understanding and treatment of triple-negative breast cancer, which is particularly aggressive and difficult to treat.
Two researchers from Vanderbilt-Ingram Cancer Center (VICC) are featured in Clinical Cancer Advances 2020: ASCO’s Annual Report on Progress Against Cancer.
Rhea Dodd is the first patient treated with an experimental cancer vaccine derived from a completely new cell engineering platform.
According to a statement on behalf of the American College of Medical Genetics and Genomics, there is insufficient evidence to recommend universal genetic testing for BRCA1/2 alone or in combination with multi-gene panels for all breast cancer patients.
Cathy Eng, MD, a national and international leader in gastrointestinal medical oncology, was recruited to VUMC from The University of Texas MD Anderson Cancer Center in Houston.
Two Vanderbilt-Ingram Cancer Center investigators have received financial support from Susan G. Komen for breast cancer research.
Accessibility Tools